NRAS and neoplasm: NRAS mutation is quite frequent in melanoma; it is present in about 15–20% of patients with advanced disease [14] and is probably responsible for the upregulation of the mitogen-activated protein kinase (MAPK) pathway, which can promote cell proliferation and tumor cell survival, leading to increased tumor aggressiveness [15,16].